TRILYTE WITH FLAVOR PACKS- polyethylene glyocol 3350, sodium chloride, sodium bicarbonate and potassium chloride powder, for solution 
Wallace Pharmaceuticals Inc.

----------

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use TRILYTE safely and effectively. See full prescribing information for TRILYTE.
 
TRILYTE (polyethylene glycol 3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution) with flavor packs
Initial U.S. Approval: 1991

INDICATIONS AND USAGE

TRILYTE is a combination of PEG 3350, an osmotic laxative, and electrolytes indicated for cleansing of the colon in preparation for colonoscopy in adults and pediatric patients aged 6 months or greater (1)

DOSAGE AND ADMINISTRATION

TRILYTE, supplied as a powder, must be reconstituted with water before its use (2.1, 5.8)
On day prior to colonoscopy, instruct patients to:
Eat a light breakfast or have clear liquids (avoid red and purple liquids) (2.2).
If adding a TRILYTE flavor pack, pour the contents of flavor powder (i.e., cherry or lemon-lime) into container prior to reconstitution (2.2).
Early in the evening prior to colonoscopy, fill container containing TRILYTE powder with lukewarm water to 4 liter fill line (2.2).
After capping container, shake vigorously several times (2.2).
Instruct patients to consume water or clear liquids during and after bowel preparation up until 2 hours before time of colonoscopy (2.3).
Adults: Drink at a rate of 240 mL (8 oz.) every 10 minutes, until 4 liters are consumed or rectal effluent is clear. For nasogastric tube (NGT), rate is 1.2 to 1.8 liters per hour (2.3)
Pediatric patients (aged 6 months or greater): Drink 25 mL/kg/hour orally or administer by NGT. Continue drinking until watery stool is clear and free of solid matter (2.3).

DOSAGE FORMS AND STRENGTHS

For oral solution: polyethylene glycol 3350 420 grams, sodium bicarbonate 5.72 grams, sodium chloride 11.2 grams, potassium chloride 1.48 grams, and flavoring ingredients 3.22 grams; supplied in one 4 liter disposable jug (3)

CONTRAINDICATIONS

Gastrointestinal (GI) obstruction, ileus, or gastric retention (4, 5.6)
Bowel perforation (4, 5.6)
Toxic colitis or toxic megacolon (4)
Known allergy or hypersensitivity to components of TRILYTE (4, 11)

WARNINGS AND PRECAUTIONS

Risk of fluid and electrolyte abnormalities, arrhythmias, seizures and renal impairment-assess concurrent medications and consider testing in some patients (5.1, 5.2, 5.3, 5.4)
Patients with renal insufficiency– use caution, ensure adequate hydration and consider testing (5.4)
Suspected GI obstruction or perforation – rule out the diagnosis before administration (4, 5.6)
Patients at risk for aspiration – observe during administration (5.7)
Not for direct ingestion – dilute and take with additional water (5.8)

ADVERSE REACTIONS

Most common adverse reactions (≥ 3%) are: nausea, abdominal fullness and bloating. Abdominal cramps, vomiting and anal irritation occur less frequently (6)

To report SUSPECTED ADVERSE REACTIONS, contact Wallace Pharmaceuticals Inc. at 1-888-444-1527 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Some drugs increase risks due to fluid and electrolyte changes (7.1)
Oral medication taken within 1 hour of start of each dose may not be absorbed properly (7.2)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 5/2017

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Dosage Overview

2.2 Administration Instructions Prior to Dosage

2.3 Dosage

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Serious Fluid and Serum Chemistry Abnormalities

5.2 Cardiac Arrhythmias

5.3 Seizures

5.4 Renal Impairment

5.5 Colonic Mucosal Ulcerations and Ischemic Colitis

5.6 Use in Patients with Significant Gastrointestinal Disease

5.7 Aspiration

5.8 Not for Direct Ingestion

6 ADVERSE REACTIONS

7 DRUG INTERACTIONS

7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities

7.2 Potential for Altered Drug Absorption

7.3 Stimulant Laxatives

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.3 Nursing Mothers

8.4 Pediatric Use

8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

*
Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

TRILYTE is indicated for bowel cleansing prior to colonoscopy in adults and pediatric patients aged 6 months or greater.

2 DOSAGE AND ADMINISTRATION

2.1 Dosage Overview

TRILYTE, supplied as a powder, must be reconstituted with water before its use; it is not for direct ingestion [see Dosage and Administration (2.2), Warnings and Precautions (5.8)]. The 4 liter reconstituted TRILYTE solution contains: 420 grams of polyethylene glycol (PEG) 3350, 5.72 grams of sodium bicarbonate, 11.2 grams of sodium chloride, and 1.4 grams of potassium chloride. TRILYTE may be used with or without one of the supplied flavor packs.

2.2 Administration Instructions Prior to Dosage

On the day prior to the colonoscopy, instruct patients to:

a)
Take only clear liquids, but avoid red and purple liquids. Patients may consume a light breakfast.
b)
If adding a TRILYTE flavor pack, pour the contents of the 3.22 gram flavor powder (i.e., cherry or lemon-lime) into the container prior to reconstitution. No additional flavorings should be added. Discard unused flavor packs. The TRILYTE flavor packs are for use only in combination with the contents of the accompanying 4 liter container.
c)
Early in the evening prior to colonoscopy, fill the supplied container containing the TRILYTE powder (and if applicable, a flavor powder) with lukewarm water (to facilitate dissolution) to the 4 liter fill line. The solution is clear and colorless when reconstituted to a final volume of 4 liters.
d)
After capping the container, shake vigorously several times to ensure that the ingredients are dissolved. When reconstituted use within 48 hours.

2.3 Dosage

The following is the recommended dose of reconstituted TRILYTE solution for adults and pediatric patients ≥ 6 months. Instruct patients they may consume water or clear liquids during the bowel preparation and after completion of the bowel preparation up until 2 hours before the time of the colonoscopy. The solution is more palatable if chilled prior to administration.

Adults: Instruct patients to drink a total of up to 4 liters at a rate of 240 mL (8 oz.) every 10 minutes, until 4 liters are consumed or the rectal effluent is clear. Rapid drinking of each portion is preferred to drinking small amounts continuously. For NGT, rate is 20 to 30 mL per minute (1.2 to 1.8 liters per hour).
Pediatric Patients ≥ 6 Months: Pediatric patients should drink 25 mL/kg/hour until the stool is watery, clear, and free of solid matter. If pediatric patients are unable to drink the reconstituted TRILYTE solution, the solution may be given by nasogastric tube (NGT). NGT administration is at the rate of 25 mL/kg/hour.

The first bowel movements should occur approximately one hour after the start of TRILYTE administration. Continue drinking until the watery stool is clear and free of solid matter.

3 DOSAGE FORMS AND STRENGTHS

For oral solution: One 4 liter jug with powder for reconstitution with water.

Each 4 liter jug contains: polyethylene glycol 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, potassium chloride 1.48 g and flavoring ingredients 3.22 g. When made up to 4 liters volume with water, the solution contains PEG 3350 31.3 mmol/L, sodium 65 mmol/L, chloride 53 mmol/L, bicarbonate 17 mmol/L and potassium 5 mmol/L.

4 CONTRAINDICATIONS

TRILYTE is contraindicated in the following conditions:

Gastrointestinal (GI) obstruction, ileus, or gastric retention
Bowel perforation
Toxic colitis or toxic megacolon
Known allergy or hypersensitivity to any component of TRILYTE [see How Supplied/Storage and Handling (16)]

5 WARNINGS AND PRECAUTIONS

5.1 Serious Fluid and Serum Chemistry Abnormalities

Advise patients to hydrate adequately before, during, and after the use of TRILYTE. Use caution in patients with congestive heart failure when replacing fluids. If a patient develops significant vomiting or signs of dehydration including signs of orthostatic hypotension after taking TRILYTE, consider performing post-colonoscopy lab tests (electrolytes, creatinine, and BUN) and treat accordingly. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures and renal impairment. Fluid and electrolyte abnormalities should be corrected before treatment with TRILYTE.

In addition, use caution when prescribing TRILYTE for patients who have conditions, or who are using medications, that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and renal impairment [see Drug Interactions (7.1)].

5.2 Cardiac Arrhythmias

There have been rare reports of serious arrhythmias associated with the use of ionic osmotic laxative products for bowel preparation. Use caution when prescribing TRILYTE for patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy). Pre-dose and post-colonoscopy ECGs should be considered in patients at increased risk of serious cardiac arrhythmias.

5.3 Seizures

There have been reports of generalized tonic-clonic seizures and/or loss of consciousness associated with use of bowel preparation products in patients with no prior history of seizures. The seizure cases were associated with electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia) and low serum osmolality. The neurologic abnormalities resolved with correction of fluid and electrolyte abnormalities.

Use caution when prescribing TRILYTE for patients with a history of seizures and in patients at increased risk of seizure, such as patients taking medications that lower the seizure threshold (e.g., tricyclic antidepressants), patients withdrawing from alcohol or benzodiazepines, or patients with known or suspected hyponatremia.

5.4 Renal Impairment

Use caution when prescribing TRILYTE for patients with impaired renal function or patients taking concomitant medications that may affect renal function (such as diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or non-steroidal anti-inflammatory drugs). Advise these patients of the importance of adequate hydration, and consider performing baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients.

5.5 Colonic Mucosal Ulcerations and Ischemic Colitis

Administration of osmotic laxative products may produce colonic mucosal aphthous ulcerations, and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of stimulant laxatives and TRILYTE may increase this risk. The potential for mucosal ulcerations resulting from the bowel preparation should be considered when interpreting colonoscopy findings in patients with known or suspect inflammatory bowel disease (IBD).

5.6 Use in Patients with Significant Gastrointestinal Disease

If gastrointestinal obstruction or perforation is suspected, perform appropriate diagnostic studies to rule out these conditions before administering TRILYTE. If a patient experiences severe bloating, distention or abdominal pain, administration should be slowed or temporarily discontinued until the symptoms abate. If gastrointestinal obstruction or perforation is suspected, appropriate studies should be performed to rule out these conditions before administration of TRILYTE.

Use with caution in patients with severe active ulcerative colitis.

5.7 Aspiration

Use with caution in patients with impaired gag reflex, unconscious, or semiconscious patients, and patients prone to regurgitation or aspiration. Such patients should be observed during administration of TRILYTE, especially if it administered via nasogastric tube.

5.8 Not for Direct Ingestion

The contents of each jug must be diluted with water to a final volume of 4 liters (4 L) and ingestion of additional water is important to patient tolerance. Direct ingestion of the undissolved powder may increase the risk of nausea, vomiting, dehydration, and electrolyte disturbances.

6 ADVERSE REACTIONS

The following adverse reactions have been identified during post-approval use of TRILYTE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Nausea, abdominal fullness and bloating are the most common adverse reactions (occurred in up to 50% of patients) to administration of TRILYTE. Abdominal cramps, vomiting and anal irritation occur less frequently. These adverse reactions are transient and usually subside rapidly. Isolated cases of urticaria, rhinorrhea, dermatitis and (rarely) anaphylactic reaction have been reported which may represent allergic reactions.

Published literature contains isolated reports of serious adverse reactions following the administration of PEG-electrolyte solution products in patients over 60 years of age. These adverse events include upper GI bleeding from Mallory-Weiss Tear, esophageal perforation, asystole, sudden dyspnea with pulmonary edema, and “butterfly-like” infiltrates on chest X-ray after vomiting and aspirating PEG.

7 DRUG INTERACTIONS

7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities

Use caution when prescribing TRILYTE for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. Consider additional patient evaluations as appropriate [see Warnings and Precautions (5.1, 5.2, 5.3, and 5.4)] in patients taking these concomitant medications.

7.2 Potential for Altered Drug Absorption

Oral medication administered within one hour of the start of administration of TRILYTE may be flushed from the gastrointestinal tract and the medication may not be absorbed properly.

7.3 Stimulant Laxatives

Concurrent use of stimulant laxatives and TRILYTE may increase the risk of mucosal ulceration or ischemic colitis. Avoid use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) while taking TRILYTE.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C

Animal reproduction studies have not been conducted with TRILYTE. It is also not known whether TRILYTE can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. TRILYTE should be given to a pregnant woman only if clearly needed.

8.3 Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TRILYTE is administered to a nursing woman.

8.4 Pediatric Use

Safety and effectiveness of TRILYTE in pediatric patients aged 6 months and older is supported by evidence from adequate and well-controlled clinical trials of TRILYTE in adults with additional safety and efficacy data from published studies of similar formulations.

Use of TRILYTE in children younger than 2 years of age should be carefully monitored for occurrence of possible hypoglycemia, as this solution has no caloric substrate. Dehydration has been reported in one child and hypokalemia has been reported in 3 children.

8.5 Geriatric Use

Clinical studies of TRILYTE did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

11 DESCRIPTION

For oral solution: Each 4 liter (4 L) TRILYTE jug contains a white to off white powder for reconstitution. TRILYTE is a combination of polyethylene glycol 3350, an osmotic laxative, and electrolytes (sodium chloride, sodium bicarbonate and potassium chloride) for oral solution.

Each 4 liter jug contains: polyethylene glycol 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, potassium chloride 1.48 g. The solution is clear and colorless when reconstituted to a final volume of 4 liters with water.

Polyethylene Glycol 3350, USP

Polyethylene Glycol 3350 Structural Formula

Sodium Bicarbonate, USP

The chemical name is NaHCO3. The average Molecular Weight is 84.01. The structural formula is:

Sodium Bicarbonate Structural Formula

Sodium Chloride, USP

The chemical name is NaCl. The average Molecular Weight: 58.44. The structural formula is:

Sodium Chloride Structural Formula

Potassium Chloride, USP

The chemical name is KCl. The average Molecular Weight: 74.55. The structural formula is:

Potassium Chloride Structural Formula

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The primary mode of action is thought to be through the osmotic effect of polyethylene glycol 3350 which causes water to be retained in the colon and produces a watery stool.

12.2 Pharmacodynamics

TRILYTE induces as diarrhea which rapidly cleanses the bowel, usually within four hours.

12.3 Pharmacokinetics

The pharmacokinetics of PEG 3350 following administration of TRILYTE were not assessed. Available pharmacokinetic information for oral PEG 3350 suggests that it is poorly absorbed.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long term studies in animals have not been performed to evaluate carcinogenic potential of TRILYTE. Studies to evaluate the possible impairment of fertility or mutagenic potential of TRILYTE have not been performed.

16 HOW SUPPLIED/STORAGE AND HANDLING

In powdered form, for oral administration as a solution following reconstitution.

TRILYTE with flavor packs (PEG 3500, sodium chloride, sodium bicarbonate and potassium chloride for oral solution) is supplied in a 4 liter bottle with an attached package containing flavor packs. This preparation is supplied in powdered form (white to off-white powder) for oral administration as a solution following reconstitution. Each 4 liter bottle contains polyethylene glycol 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, potassium chloride 1.48 g. Each flavor pack contains 3.22 g of flavoring ingredients. When made up to 4 liters volume with water, the solution contains PEG 3350 31.3 mmol/L, sodium 65 mmol/L, chloride 53 mmol/L, bicarbonate 17 mmol/L and potassium 5 mmol/L.

TRILYTE with flavor packs     4 liter     NDC 51525-6831-4

Storage: Store in sealed container at 25ºC (77ºF); excursions permitted to 15º to 30ºC (59º to 86ºF). [See USP Controlled Room Temperature.] When reconstituted, keep solution refrigerated. Use within 48 hours. Discard unused portion.

Keep out of reach of children.

17 PATIENT COUNSELING INFORMATION

See FDA-Approved Patient Labeling (Medication Guide). Instruct patients:

To let you know if they have trouble swallowing or are prone to regurgitation or aspiration.
Not to take other laxatives while they are taking TRILYTE.
To consume water or clear liquids during the bowel preparation and after completion of the bowel preparation up until 2 hours before the time of the colonoscopy.
That if they experience severe bloating, distention or abdominal pain, the administration of the solution should be slowed or temporarily discontinued until the symptoms abate. Advise patients to report these events to their health care provider.
That if they have hives, rashes, or any allergic reaction, they should discontinue the medication and contact their health care provider. Medication should be discontinued until they speak to their physician.
To contact their healthcare provider if they develop signs and symptoms of dehydration [see Warnings and Precautions (5.1)].
That oral medication administered within one hour of the start of administration of TRILYTE solution may be flushed from the GI tract and the medication may not be absorbed completely.

IN-6831-03 Rev 5/2017 CIA71673D

Medication Guide

TRILYTE
(traI-laIt)
(PEG 3350, sodium chloride, sodium bicarbonate and potassium chloride oral solution)

Read this Medication Guide before you start taking TRILYTE. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.

 

What is the most important information I should know about TRILYTE?

TRILYTE and other osmotic bowel preparations can cause serious side effects, including:

Serious loss of body fluid (dehydration) and changes in blood salts (electrolytes) in your blood.

These changes can cause:

abnormal heartbeats that can cause death
seizures. This can happen even if you have never had a seizure.
kidney problems

Your chance of having fluid loss and changes in body salts with TRILYTE is higher if you:

have heart problems
have kidney problems
take water pills or non-steroidal anti-inflammatory drugs (NSAIDS)

Tell your healthcare provider right away if you have any of these symptoms of a loss of too much body fluid (dehydration) while taking TRILYTE:

vomiting that prevents you from keeping down the solution
dizziness
urinating less often than normal
headache

See Section “What are the possible side effects of TRILYTE” for more information about side effects.

 

What is TRILYTE?

TRILYTE is a prescription medicine used by adults to clean the colon before a colonoscopy. TRILYTE cleans your colon by causing you to have diarrhea. Cleaning your colon helps your healthcare provider see the inside of your colon more clearly during your colonoscopy.

 

TRILYTE is safe and effective for use in pediatric patients aged 6 months and older.

 

Who should not take TRILYTE?

Do not take TRILYTE if your healthcare provider has told you that you have:

a blockage in your bowel (obstruction)
an opening in the wall of your stomach or intestine (bowel perforation)
problems with food and fluid emptying from your stomach (gastric retention)
a very dilated intestine (bowel)
an allergy to any of the ingredients in TRILYTE. See the end of this leaflet for a complete list of ingredients in TRILYTE.

What should I tell my healthcare provider before taking TRILYTE? Before you take TRILYTE, tell your healthcare provider if you:

have heart problems
have stomach or bowel problems
have ulcerative colitis
have problems with swallowing or gastric reflux
have a history of seizures
are withdrawing from drinking alcohol
have a low blood salt (sodium) level
have kidney problems
any other medical conditions
are pregnant. It is not known if TRILYTE will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant.
are breastfeeding or plan to breastfeed. It is not known if TRILYTE passes into your breast milk. You and your healthcare provider should decide if you will take TRILYTE while breastfeeding.

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.

 

TRILYTE may affect how other medicines work. Medicines taken by mouth may not be absorbed properly when taken within 1 hour before the start of TRILYTE.

 

Especially tell your healthcare provider if you take:

medicines for blood pressure or heart problems
medicines for kidney problems
medicines for seizures
water pills (diuretics)
non-steroidal anti-inflammatory medicines (NSAID) pain medicines
laxatives

Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure if you are taking any of the medicines listed above.

 

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

 

How should I take TRILYTE?  

 

You must read, understand, and follow these instructions to take TRILYTE the right way.

Take TRILYTE exactly as your healthcare provider tells you to take it.
Drink 240 mL (8 oz.) every 10 minutes. Rapid drinking of each portion is better than drinking small amounts.
The first bowel movement should occur approximately one hour after you start drinking the solution.
You may experience some abdominal bloating and distention before the bowels start to move. If severe discomfort or distention occur, stop drinking temporarily or drink each portion at longer intervals until the discomfort goes away.
Continue drinking until the watery stool is clear and free of solid matter. This usually requires 3 liters and it is best to drink all of the solution.
Do not take undissolved TRILYTE powder that has not been mixed with water (diluted), it may increase your risk of nausea, vomiting and fluid loss (dehydration).
Each jug of TRILYTE must be reconstituted with water (diluted) to 4 liters total volume before drinking.
Do not take other laxatives while taking TRILYTE.
Do not eat solid foods on the day before your colonoscopy and until after your colonoscopy. Drink only clear liquids:
o
the day before your colonoscopy
o
while taking TRILYTE
o
after taking TRILYTE until 2 hours before your colonoscopy

What are the possible side effects of TRILYTE?

TRILYTE can cause serious side effects, including:

See Section “What is the most important information I should know about TRILYTE?”
changes in certain blood tests. Your healthcare provider may do blood tests after you take TRILYTE to check your blood for changes. Tell your healthcare provider if you have any symptoms of too much fluid loss, including:
o
vomiting
o
nausea
o
bloating
o
dizziness
o
stomach (abdominal) cramping
o
headache
o
urinate less than usual
o
trouble drinking clear liquid
heart problems. TRILYTE may cause irregular heartbeats.
seizures
ulcers of the bowel or bowel problems (ischemic colitis). Tell your healthcare provider right away if you have severe stomach-area (abdomen) pain or rectal bleeding.

The most common side effects of TRILYTE include:

nausea
stomach (abdominal) fullness
bloating
stomach (abdominal) cramps
vomiting
anal irritation

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

 

These are not all the possible side effects of TRILYTE. For more information, ask your healthcare provider or pharmacist.

 

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

 

How should I store TRILYTE?

Store TRILYTE at room temperature, between 15º to 30°C (59º to 86°F).

Keep TRILYTE and all medicines out of the reach of children.

General information about the safe and effective use of TRILYTE.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TRILYTE for a condition for which it was not prescribed. Do not give TRILYTE to other people, even if they are going to have the same procedure you are. It may harm them.

 

This Medication Guide summarizes important information about TRILYTE. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information that is written for healthcare professionals.

 

For more information, call Wallace Pharmaceuticals Inc. at 1-888-444-1527.

 

What are the ingredients in TRILYTE?

Active ingredients: polyethylene glycol 3350, sodium sulfate, sodium bicarbonate, sodium chloride, and potassium chloride.

 

Inactive ingredients: cherry flavoring, lemon-lime flavoring (flavor packs only)

 

This Medication Guide has been approved by the U.S. Food and Drug Administration.

 

Manufactured by: Kremers Urban Pharmaceuticals Inc., Seymour IN 47274 for Wallace Pharmaceuticals Inc. Somerset, NJ 08873-4120

 

For Medical Inquiries call Wallace Pharmaceuticals Inc. at 1-888-444-1527.

 

©2017 Wallace Pharmaceuticals Inc., a Mylan company

TRILYTE is a registered trademark of Alaven Pharmaceutical LLC, a Mylan company

WALLACE and the “W” logo are trademarks of Wallace Pharmaceuticals Inc., a Mylan company

IN-6831-03 Rev 5/2017 CIA71814A

PRINCIPAL DISPLAY PANEL – 4 liters

NDC 51525-6831-4

Rx Only

4 liters

Note to pharmacist: Dispense
bottle and all attached flavor packs to
patient. Dispense the accompanying
Medication Guide to each patient.

TriLyte® with flavor packs
(PEG 3350, sodium chloride, sodium bicarbonate
and potassium chloride for oral solution)

When reconstituted with water to a volume for 4 liters, this
solution contains PEG 3350 31.3 mmol/L, sodium 65 mmol/L,
chloride 53 mmol/L, bicarbonate 17 mmol/L and potassium
5 mmol/L.

This package contains the following ingredients:
Polyethylene Glycol 3350        420 g
Sodium Bicarbonate          5.72 g
Sodium Chloride           11.2 g
Potassium Chloride           1.48 g

Store in sealed container at 25ºC (77ºF); excursions
permitted between 15º to 30ºC (59º to 86ºF). [See USP
Controlled Room Temperature.]

See base label for mixing information.

WALLACE
PHARMACEUTICALS

LB-683104-03    Rev. 5/2017

CIA71673D

TriLyte with flavor packs Label
TRILYTE  WITH FLAVOR PACKS
polyethylene glyocol 3350, sodium chloride, sodium bicarbonate and potassium chloride powder, for solution
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:51525-6831
Route of AdministrationORAL, NASOGASTRIC
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
POLYETHYLENE GLYCOL 3350 (UNII: G2M7P15E5P) (POLYETHYLENE GLYCOL 3350 - UNII:G2M7P15E5P) POLYETHYLENE GLYCOL 3350420 g  in 4 L
SODIUM CHLORIDE (UNII: 451W47IQ8X) (SODIUM CATION - UNII:LYR4M0NH37) SODIUM CHLORIDE11.2 g  in 4 L
SODIUM BICARBONATE (UNII: 8MDF5V39QO) (SODIUM CATION - UNII:LYR4M0NH37) SODIUM BICARBONATE5.72 g  in 4 L
POTASSIUM CHLORIDE (UNII: 660YQ98I10) (POTASSIUM CATION - UNII:295O53K152) POTASSIUM CHLORIDE1.48 g  in 4 L
Product Characteristics
ColorWHITEScore    
ShapeSize
FlavorLEMON, LIME (lemon-lime) , CHERRY, CITRUS (citrus-berry) , ORANGE, PINEAPPLEImprint Code
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:51525-6831-44 L in 1 BOTTLE; Type 0: Not a Combination Product10/01/2016
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA07649110/01/2016
Labeler - Wallace Pharmaceuticals Inc. (962531955)

Revised: 5/2017
Document Id: 0d80cbb9-e846-443c-bbfe-64a565f61663
Set id: 486598b1-0358-11e3-8ffd-0800200c9a66
Version: 3
Effective Time: 20170524
 
Wallace Pharmaceuticals Inc.